Cartesian Therapeutics, Inc. (RNAC) Net income 2016–2025
Cartesian Therapeutics, Inc. (RNAC) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$130.3MFY2025 · since FY2016: -$36.2M → -$130.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$130.3M | -68.3% |
| FY2024 | -$77.4M | +64.8% |
| FY2023 | -$219.7M | -721.0% |
| FY2022 | $35.4M | +237.7% |
| FY2021 | -$25.7M | +62.7% |
| FY2020 | -$68.9M | -24.4% |
| FY2019 | -$55.4M | +15.3% |
| FY2018 | -$65.3M | -0.0% |
| FY2017 | -$65.3M | -80.4% |
| FY2016 | -$36.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More RNAC financial trends
RNAC RevenueRNAC Net marginRNAC Gross profitRNAC Gross marginRNAC Operating incomeRNAC Operating marginRNAC Operating cash flowRNAC Free cash flowRNAC Capital expendituresRNAC Return on equityRNAC Stock buybacksRNAC Dividends paidRNAC Total assetsRNAC Total liabilitiesRNAC Shareholders’ equityRNAC overview →